Halozyme Therapeutics (HALO) Tops Q3 EPS by 6c; Raises Outlook

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million.

GUIDANCE:

Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69. Halozyme Therapeutics sees FY2020 revenue of $250-260 million, versus the consensus of $235.94 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating